[
  {
    "ts": "2025-09-02T15:09:00+00:00",
    "headline": "Cytokinetics Stock Jumps. The Biotech’s Heart Drug Wows.",
    "summary": "Trial results for aficamten were presented to cardiologists over the weekend. One analyst said the drug could be “best-in-class therapy.”",
    "url": "https://www.barrons.com/articles/cytokinetics-stock-heart-drug-bristol-myers-squibb-e6e6af83?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "038c1d6f-3582-3ecb-9a64-69f5f1127075",
      "content": {
        "id": "038c1d6f-3582-3ecb-9a64-69f5f1127075",
        "contentType": "STORY",
        "title": "Cytokinetics Stock Jumps. The Biotech’s Heart Drug Wows.",
        "description": "",
        "summary": "Trial results for aficamten were presented to cardiologists over the weekend. One analyst said the drug could be “best-in-class therapy.”",
        "pubDate": "2025-09-02T15:09:00Z",
        "displayTime": "2025-09-02T15:09:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/038c1d6f-3582-3ecb-9a64-69f5f1127075/cytokinetics-stock-jumps-the.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/704fa877a41716e4eaafcbe3087afc1d",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/L_b46TIwgR_Zh8Xiqe5MIA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/704fa877a41716e4eaafcbe3087afc1d.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1NyQlXVAr9xhyeyfKmajJA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/704fa877a41716e4eaafcbe3087afc1d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/cytokinetics-stock-heart-drug-bristol-myers-squibb-e6e6af83?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "CYTK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-02T14:10:00+00:00",
    "headline": "Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?",
    "summary": "Bristol Myers expects mid to high-single-digit sales growth for Opdivo and Qvantig in 2025 as approvals and launches gain momentum.",
    "url": "https://finance.yahoo.com/news/opdivo-opdivo-qvantig-drive-bmys-141000500.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "60b64ec7-1d66-37c3-b569-53d484753618",
      "content": {
        "id": "60b64ec7-1d66-37c3-b569-53d484753618",
        "contentType": "STORY",
        "title": "Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?",
        "description": "",
        "summary": "Bristol Myers expects mid to high-single-digit sales growth for Opdivo and Qvantig in 2025 as approvals and launches gain momentum.",
        "pubDate": "2025-09-02T14:10:00Z",
        "displayTime": "2025-09-02T14:10:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AZ1NFKr1Arip4UWINeWStw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zL5_evNVQm1N5N.bc6WldQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/opdivo-opdivo-qvantig-drive-bmys-141000500.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/opdivo-opdivo-qvantig-drive-bmys-141000500.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "RHHBY"
            },
            {
              "symbol": "RHHVF"
            },
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-02T12:00:00+00:00",
    "headline": "SystImmune, Inc. to Present New iza-bren (izalontamab brengitecan) Data in Non-Small Cell Lung Cancer at WCLC Congress 2025",
    "summary": "SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced that two abstracts for iza-bren (izalontamab brengitecan), a potentially first-in-class EGFRxHER3 bispecific antibody drug conjugate (ADC), will be presented at the World Conference on Lung Cancer (WCLC) 2025 Annual Meeting taking place September 6 – 9 in Barcelona, Spain. Iza-bren is jointly developed by SystImmune and Bristol Myers Squibb under a collaboration and exclusive license agreement in territories o",
    "url": "https://finance.yahoo.com/news/systimmune-inc-present-iza-bren-120000790.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "bf58cea6-f2da-3808-839d-64f35aba9879",
      "content": {
        "id": "bf58cea6-f2da-3808-839d-64f35aba9879",
        "contentType": "STORY",
        "title": "SystImmune, Inc. to Present New iza-bren (izalontamab brengitecan) Data in Non-Small Cell Lung Cancer at WCLC Congress 2025",
        "description": "",
        "summary": "SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced that two abstracts for iza-bren (izalontamab brengitecan), a potentially first-in-class EGFRxHER3 bispecific antibody drug conjugate (ADC), will be presented at the World Conference on Lung Cancer (WCLC) 2025 Annual Meeting taking place September 6 – 9 in Barcelona, Spain. Iza-bren is jointly developed by SystImmune and Bristol Myers Squibb under a collaboration and exclusive license agreement in territories o",
        "pubDate": "2025-09-02T12:00:00Z",
        "displayTime": "2025-09-02T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/a2c51215c5ec63b757111724cd5e99fd",
          "originalWidth": 400,
          "originalHeight": 200,
          "caption": "(PRNewsfoto/SystImmune Inc.)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9O6MLWScjve8x12UaJ5fdQ--~B/aD0yMDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a2c51215c5ec63b757111724cd5e99fd.cf.webp",
              "width": 400,
              "height": 200,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w3IY14xgSYxhxZXyRr5iJA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a2c51215c5ec63b757111724cd5e99fd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/systimmune-inc-present-iza-bren-120000790.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/systimmune-inc-present-iza-bren-120000790.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-02T07:29:24+00:00",
    "headline": "Bristol-Myers Squibb Company (BMY) Launches $300M Immunology Spinout with Bain Capital",
    "summary": "We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Bristol-Myers Squibb Company stands eighth among them. Bristol-Myers Squibb Company (NYSE:BMY), a global biopharma leader, is making bold moves to strengthen its immunology presence through strategic partnerships and a growing pipeline. In July 2025, the company announced a […]",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-company-bmy-072924567.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "ebcdfeb3-523d-34e2-bc0f-b985d3df3281",
      "content": {
        "id": "ebcdfeb3-523d-34e2-bc0f-b985d3df3281",
        "contentType": "STORY",
        "title": "Bristol-Myers Squibb Company (BMY) Launches $300M Immunology Spinout with Bain Capital",
        "description": "",
        "summary": "We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Bristol-Myers Squibb Company stands eighth among them. Bristol-Myers Squibb Company (NYSE:BMY), a global biopharma leader, is making bold moves to strengthen its immunology presence through strategic partnerships and a growing pipeline. In July 2025, the company announced a […]",
        "pubDate": "2025-09-02T07:29:24Z",
        "displayTime": "2025-09-02T07:29:24Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/2c8f851c326321f2c94ddd4776afda17",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Bristol-Myers Squibb Company (BMY) Launches $300M Immunology Spinout with Bain Capital",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xYG5Yb2Ryw09lOYtZg2v7Q--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/2c8f851c326321f2c94ddd4776afda17.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NF09K7qUiav0AMXeYxdZeg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/2c8f851c326321f2c94ddd4776afda17.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-company-bmy-072924567.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-company-bmy-072924567.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]